| Symbol | LYEL |
|---|---|
| Name | LYELL IMMUNOPHARMA, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 201 HASKINS WAY,SUITE 301, SOUTH SAN FRANCISCO, California, 94080, United States |
| Telephone | +1 650 695-0677 |
| Fax | — |
| — | |
| Website | https://www.lyell.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001806952 |
| Description | Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors. Its pipeline includes CARs (Chimeric antigen receptors), TILs (Tumor-infiltrating lymphocytes), and TCRs (T cell receptors). Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - Lyell Immunopharma, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001012975-26-000439 <b>Size:</b> 27 KB
Read moreNew Form SCHEDULE 13G/A - Lyell Immunopharma, Inc. <b>Filed:</b> 2026-05-11 <b>AccNo:</b> 0001193125-26-216076 <b>Size:</b> 9 KB
Read moreNew Form SCHEDULE 13G/A - Lyell Immunopharma, Inc. <b>Filed:</b> 2026-05-08 <b>AccNo:</b> 0001168404-26-000021 <b>Size:</b> 10 KB
Read moreLyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026
Read moreNew Form ARS - Lyell Immunopharma, Inc. <b>Filed:</b> 2026-04-24 <b>AccNo:</b> 0001140361-26-016690 <b>Size:</b> 4 MB
Read moreNew Form DEFA14A - Lyell Immunopharma, Inc. <b>Filed:</b> 2026-04-24 <b>AccNo:</b> 0001140361-26-016688 <b>Size:</b> 1 MB
Read moreNew Form DEF 14A - Lyell Immunopharma, Inc. <b>Filed:</b> 2026-04-24 <b>AccNo:</b> 0001140361-26-016686 <b>Size:</b> 5 MB
Read moreNew Form SCHEDULE 13G - Lyell Immunopharma, Inc. <b>Filed:</b> 2026-04-21 <b>AccNo:</b> 0001193125-26-165277 <b>Size:</b> 11 KB
Read moreNew Form EFFECT - Lyell Immunopharma, Inc. <b>Filed:</b> 2026-04-14 <b>AccNo:</b> 9999999995-26-001185 <b>Size:</b> 1 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07188558 | A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell T… | Phase3 | Large B-cell Lymphoma | Recruiting | 2026-01-12 | 2032-01-01 | ClinicalTrials.gov |
| NCT06153095 | A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupu… | Phase1 | Systemic Lupus Erythematosus | Withdrawn | 2024-02-15 | 2025-01-09 | ClinicalTrials.gov |
| NCT05891197 | A Biomarker Screening Protocol for Participants With Solid Tumors | — | Triple Negative Breast Cancer | Terminated | 2023-05-19 | 2025-02-05 | ClinicalTrials.gov |
| NCT05826535 | Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma | Phase1 | Relapsed Non-Hodgkin Lymphoma | Recruiting | 2023-05-09 | 2031-06-30 | ClinicalTrials.gov |
| NCT05573035 | A Study to Investigate LYL845 in Adults With Solid Tumors | Phase1 | Melanoma | Terminated | 2022-12-19 | 2025-01-09 | ClinicalTrials.gov |
| NCT05319314 | GCC19CART for Patients With Metastatic Colorectal Cancer | Phase1 | Colorectal Cancer | Recruiting | 2022-08-01 | 2032-06-01 | ClinicalTrials.gov |
| NCT05274451 | A Study to Investigate LYL797 in Adults With Solid Tumors | Phase1 | Triple Negative Breast Cancer | Terminated | 2022-03-29 | 2024-11-27 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Cyclophosphamide | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| Fludarabine | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| Rondecabtagene autoleucel (ronde-cel) | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| Cyclophosphamide | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| Fludarabine | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| Rondecabtagene autoleucel (ronde-cel) | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| Cyclophosphamide | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| Fludarabine | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| Rondecabtagene autoleucel (ronde-cel) | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| Cyclophosphamide | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| Fludarabine | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| Rondecabtagene autoleucel (ronde-cel) | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| Cyclophosphamide | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| Fludarabine | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| Rondecabtagene autoleucel (ronde-cel) | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| Cyclophosphamide | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| Fludarabine | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| Rondecabtagene autoleucel (ronde-cel) | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| Cyclophosphamide | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| Fludarabine | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| Rondecabtagene autoleucel (ronde-cel) | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| Cyclophosphamide | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| Fludarabine | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| Rondecabtagene autoleucel (ronde-cel) | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| Cyclophosphamide | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| Fludarabine | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| Rondecabtagene autoleucel (ronde-cel) | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| Cyclophosphamide | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| Fludarabine | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| Rondecabtagene autoleucel (ronde-cel) | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| IMPT-514 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | WITHDRAWN | NCT06153095 |
| LYL845 | Other | Phase PHASE1 | Melanoma | TERMINATED | NCT05573035 |
| LYL797 | Other | Phase PHASE1 | Triple Negative Breast Cancer | TERMINATED | NCT05274451 |
| GCC19CART | Other | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT05319314 |
| lisocabtagene maraleucel | Other | Phase PHASE3 | Large B-cell Lymphoma | RECRUITING | NCT07188558 |
| axicabtagene ciloleucel | Other | Phase PHASE3 | Large B-cell Lymphoma | RECRUITING | NCT07188558 |
| rondecabtagene autoleucel | Other | Phase PHASE3 | Large B-cell Lymphoma | RECRUITING | NCT07188558 |
| Cyclophosphamide | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| Fludarabine | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| Rondecabtagene autoleucel (ronde-cel) | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| Cyclophosphamide | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| Fludarabine | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| Rondecabtagene autoleucel (ronde-cel) | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| lisocabtagene maraleucel | BIOLOGICAL | Phase PHASE3 | Large B-cell Lymphoma | RECRUITING | NCT07188558 |
| axicabtagene ciloleucel | BIOLOGICAL | Phase PHASE3 | Large B-cell Lymphoma | RECRUITING | NCT07188558 |
| rondecabtagene autoleucel | BIOLOGICAL | Phase PHASE3 | Large B-cell Lymphoma | RECRUITING | NCT07188558 |
| IMPT-514 | BIOLOGICAL | Phase PHASE1 | Systemic Lupus Erythematosus | WITHDRAWN | NCT06153095 |
| Cyclophosphamide | DRUG | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| Fludarabine | DRUG | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| LYL314 | DRUG | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | RECRUITING | NCT05826535 |
| LYL845 | BIOLOGICAL | Phase PHASE1 | Melanoma | TERMINATED | NCT05573035 |
| GCC19CART | DRUG | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT05319314 |
| LYL797 | BIOLOGICAL | Phase PHASE1 | Triple Negative Breast Cancer | TERMINATED | NCT05274451 |